Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: Role of oxidative stress pathway genes

Schizophrenia Research

Volumn 92, Issue 1-3, 2007, Pages 278-279

  Thelma, B K ^a   Tiwari, Arun K ^a   Deshpande, Smita N ^b   Lerer, Bernard ^c   Nimgaonkar, Vishwajit L ^d  

^a UNIVERSITY OF DELHI   (India)

^b DR RAM MANOHAR LOHIA HOSPITAL   (India)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE TRANSFERASE; NEURONAL NITRIC OXIDE SYNTHASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE:QUINONE OXIDOREDUCTASE 1; OXIDOREDUCTASE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ALLELISM; CEREBROSPINAL FLUID ANALYSIS; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; LETTER; LIPID PEROXIDATION; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DYSKINESIA, DRUG-INDUCED; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; NEURAL PATHWAYS; OXIDATION-REDUCTION; OXIDATIVE STRESS; SCHIZOPHRENIA;

EID: 34247107021     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.12.019     Document Type: Letter

References (11)

1. Adler L.A., Rotrosen J., Edson R., Lavori P., Lohr J., Hitzemann R., Raisch D., Caligiuri M., and Tracy K. Vitamin E treatment for Tardive Dyskinesia. Veterans Affairs Cooperative Study#394 Study Group. Arch. Gen. Psychiatry 56 (1999) 836-841
2. Deshpande S.N., Varma P.G., Semwal P., Rao A.R., Bhatia T., Nimgaonkar V.L., Lerer B., and Thelma B.K. II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatr. Genet. 15 (2005) 157-158
3. Forstermann U., and Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113 (2006) 1708-1714
4. Lohr J.B., Kuczenski R., and Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17 (2003) 47-62
5. Muller D.J., Shinkai T., De Luca V., and Kennedy J.L. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J. 4 (2004) 77-87
6. Sadan O., Bahat-Stromza M., Gilgun-Sherki Y., Atlas D., Melamed E., and Offen D. A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia. Clin. Neuropharmacol. 28 (2005) 285-288
7. Siegel D., Gustafson D.L., Dehn D.L., Han J.Y., Boonchoong P., Berliner L.J., and Ross D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol. Pharmacol. 65 (2004) 1238-1247
8. Srivastava V., Varma P.G., Prasad S., Semwal P., Nimgaonkar V.L., Lerer B., Deshpande S.N., and Thelma B.K. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet. Genomics 16 (2006) 111-117
9. Tiwari A.K., Deshpande S.N., Rao A.R., Bhatia T., Mukit S.R., Shriharsh V., Lerer B., Nimgaonkar V.L., and Thelma B.K. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 polymorphisms. Pharmacogenomics J. 5 (2005) 60-69
10. Tiwari A.K., Deshpande S.N., Rao A.R., Bhatia T., Mukit S.R., Shriharsh V., Lerer B., Nimgaonkar V.L., and Thelma B.K. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr. Res. 75 (2005) 21-26
11. Tiwari A.K., Deshpande S.N., Lerer B., Nimgaonkar V.L., and Thelma B.K. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C > T polymorphism. Pharmacogenomics J. (2006) 10.1038/sj.tpj.6500415 (Sep 12)